Genomics in multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 112, Issue 7, 2010, Pages 621-624

  Habek, Mario ^a   Borovečki, Fran ^a,b   Brinar, Vesna V ^a  

^a KBC Zagreb   (Croatia)

^b Center for Translational and Clinical Research   (Croatia)

Author keywords

Biomarkers; Genomics; Microarrays; Multiple sclerosis

Indexed keywords

CHEMOKINE RECEPTOR; COMPLEMENTARY DNA; DUFFY BINDING PROTEIN; INTERFERON REGULATORY FACTOR 2; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG; GENETIC MARKER;

BLOOD SAMPLING; DISEASE COURSE; GENOMICS; HUMAN; MULTIPLE SCLEROSIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN LEVEL; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETICS; PHYSIOLOGY;

BRAIN CHEMISTRY; GENE EXPRESSION; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MULTIPLE SCLEROSIS;

EID: 77955660586     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.03.028     Document Type: Article

References (36)

1. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine Relapses and progression of disability in multiple sclerosis N Engl J Med 343 2000 1430 1438
2. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
3. H.L. Weiner Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease Arch Neurol 61 2004 1613 1615
4. A. Lutterotti, T. Berger, and M. Reindl Biological markers for multiple sclerosis Curr Med Chem 14 2007 1956 1965
5. B. Bielekova, and R. Martin Development of biomarkers in multiple sclerosis Brain 127 2004 1463 1478
6. M. Comabella, and R. Martin Genomics in multiple sclerosis - current state and future directions J Neuroimmunol 187 2007 1 8
7. D.J. Duggan, M. Bittner, Y. Chen, P. Meltzer, and J.M. Trent Expression profiling using cDNA microarrays Nat Genet 21 1999 10 14 (Pubitemid 29031485)
8. J.C. Barrett, and E.S. Kawasaki Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression Drug Discov Today 8 2003 134 141
9. L.W. Whitney, S.K. Ludwin, H.F. McFarland, and W.E. Biddison Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions J Neuroimmunol 121 2001 40 48
10. M.A.Q.C. Consortium The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nat Biotechnol 24 2006 1151 1161
11. A. Brazma, P. Hingamp, J. Quackenbush, G. Sherlock, P. Spellman, and C. Stoeckert Minimum information about a microarray experiment (MIAME)-toward standards for microarray data Nat Genet 29 2001 365 371
12. L.W. Whitney, K.G. Becker, N.J. Tresser, C.I. Caballero-Ramos, P.J. Munson, and V.V. Prabhu Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays Ann Neurol 46 1999 425 428
13. R. Bomprezzi, M. Ringnér, S. Kim, M.L. Bittner, J. Khan, and Y. Chen Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease Hum Mol Genet 12 2003 2191 2199
14. M. Mandel, M. Gurevich, R. Pauzner, N. Kaminski, and A. Achiron Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus Clin Exp Immunol 138 2004 164 170
15. L. Tajouri, A.S. Mellick, K.J. Ashton, A.E. Tannenberg, R.M. Nagra, and W.W. Tourtellotte Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis Brain Res Mol Brain Res 119 2003 170 183
16. M.P. Mycko, R. Papoian, U. Boschert, C.S. Raine, and K.W. Selmaj Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis Clin Neurol Neurosurg 106 2004 223 229
17. M.P. Mycko, R. Papoian, U. Boschert, C.S. Raine, and K.W. Selmaj cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity Brain 126 2003 1048 1057
18. C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, and H. Garren Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat Med 8 2002 500 508
19. R.L. Lindberg, C.J. De Groot, U. Certa, R. Ravid, F. Hoffmann, and L. Kappos Multiple sclerosis as a generalized CNS disease - comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS J Neuroimmunol 152 2004 154 167
20. U. Graumann, R. Reynolds, A.J. Steck, and N. Schaeren-Wiemers Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult Brain Pathol 13 2003 554 573
21. R. Dutta, J. McDonough, X. Yin, J. Peterson, A. Chang, and T. Torres Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients Ann Neurol 59 2006 478 489
22. P. Cunnea, J. McMahon, E. O'Connell, K. Mashayekhi, U. Fitzgerald, and S. McQuaid Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels Acta Neuropathol 2009 [Epub ahead of print]
23. J. Kinter, T. Zeis, and N. Schaeren-Wiemers RNA profiling of MS brain tissues Int MS J 15 2008 51 58
24. A.R. Whitney, M. Diehn, S.J. Popper, A.A. Alizadeh, J.C. Boldrick, and D.A. Relman Individuality and variation in gene expression patterns in human blood Proc Natl Acad Sci USA 100 2003 1896 1901
25. J.P. Radich, M. Mao, S. Stepaniants, M. Biery, J. Castle, and T. Ward Individual-specific variation of gene expression in peripheral blood leukocytes Genomics 83 2004 980 988
26. R. Goertsches, and U.K. Zettl MS therapy research applying genome-wide RNA profiling of peripheral blood Int MS J 14 2007 98 107
27. M. Ramanathan, B. Weinstock-Guttman, L.T. Nguyen, D. Badgett, C. Miller, and K. Patrick In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects J Neuroimmunol 116 2001 213 219
28. A. Achiron, M. Gurevich, N. Friedman, N. Kaminski, and M. Mandel Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity Ann Neurol 55 2004 410 417
29. K.P. Wandinger, C.S. Stürzebecher, B. Bielekova, G. Detore, A. Rosenwald, and L.M. Staudt Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes Ann Neurol 50 2001 349 357
30. F. Koike, J. Satoh, S. Miyake, T. Yamamoto, M. Kawai, and S. Kikuchi Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis J Neuroimmunol 139 2003 109 118
31. S. Stürzebecher, K.P. Wandinger, A. Rosenwald, M. Sathyamoorthy, A. Tzou, and P. Mattar Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis Brain 126 2003 1419 1429
32. B. Weinstock-Guttman, D. Badgett, K. Patrick, L. Hartrich, R. Santos, and D. Hall Genomic effects of IFN-beta in multiple sclerosis patients J Immunol 171 2003 2694 2702
33. P. Serrano-Fernández, S. Möller, R. Goertsches, H. Fiedler, D. Koczan, and H.J. Thiesen Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis Autoimmunity 2009 [Epub ahead of print]
34. R.H. Goertsches, M. Hecker, D. Koczan, P. Serrano-Fernandez, S. Moeller, and H.J. Thiesen Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS Pharmacogenomics 11 2010 147 161
35. A. Achiron, A. Feldman, and M. Gurevich Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis Dis Markers 27 2009 63 73
36. K.P. Wandinger, C.S. Sturzebecher, B. Bielekova, G. Detore, A. Rosenwald, and L.M. Staudt Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes Ann Neurol 50 2001 349 357